This review discusses selecting among unrelated, cord blood, and haploidentical grafts for patients with Ph-negative ALL in CR1 when an HLA-matched related donor is unavailable. The authors review research showing that HLA-matched unrelated donor HCT can result in survival comparable to related donor HCT, with four-year survival of 62% and 65%, respectively. Four-year survival of 57% can be achieved in unrelated cord blood transplantation. According to the authors, this therapy is also appropriate, especially for young patients without an HLA-matched unrelated donor or those in urgent need of HCT. They recommend that haploidentical donor HCT is best reserved for patients achieving CR, who can have three-year survival of up to 65%, but only 5-7% in non-CR.
Nishiwaki S, et al. Bone Marrow Transplant
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: Comparing HCT Donor Options in Ph- ALL
Nov 2013